Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vernakalant - Correvio Pharma

X
Drug Profile

Vernakalant - Correvio Pharma

Alternative Names: Brinavess; Kynapid; MK-6621; RSD-1235; Vernakalant-hydrochloride

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardiome Pharma
  • Developer Aspen Pharmacare; ATCO Laboratories; Cipher Pharmaceuticals; Correvio Pharma
  • Class Anisoles; Antiarrhythmics; Cyclohexanes; Pyrrolidines; Small molecules
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation

Most Recent Events

  • 18 Feb 2021 No recent reports of development identified - Preregistration for Atrial fibrillation in Pakistan (IV)
  • 27 May 2020 Correvio Pharma has been acquired by ADVANZ PHARMA
  • 24 Dec 2019 Correvio Pharma intends to resubmit NDA for Atrial fibrillation in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top